Richard Kones

Summary

Country: USA

Publications

  1. pmc Recent advances in the management of chronic stable angina II. Anti-ischemic therapy, options for refractory angina, risk factor reduction, and revascularization
    Richard Kones
    Cardiometabolic Research Institute, Houston, Texas 77055, USA
    Vasc Health Risk Manag 6:749-74. 2010
  2. pmc Mitochondrial therapy for Parkinson's disease: Neuroprotective pharmaconutrition may be disease-modifying
    Richard Kones
    Cardiometabolic Research Institute, Houston, TX, USA
    Clin Pharmacol 2:185-98. 2010
  3. doi Reducing residual risk: modern pharmacochemistry meets old-fashioned lifestyle and adherence improvement
    Richard Kones
    Cardiometabolic Research Institute Inc, 8181 Fannin Street, U314 Houston, TX 77055, USA
    Ther Adv Cardiovasc Dis 7:169-82. 2013
  4. ncbi The Jupiter study, CRP screening, and aggressive statin therapy-implications for the primary prevention of cardiovascular disease
    Richard Kones
    Cardiometabolic Research Institute, Houston, TX 77054 USA
    Ther Adv Cardiovasc Dis 3:309-15. 2009
  5. doi Oxygen therapy for acute myocardial infarction-then and now. A century of uncertainty
    Richard Kones
    Cardiometabolic Research Institute, Houston, TX, USA
    Am J Med 124:1000-5. 2011
  6. pmc Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey
    Richard Kones
    The Cardiometabolic Research Institute, Houston, TX 77054, USA
    Drug Des Devel Ther 5:325-80. 2011
  7. pmc Rosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease--a perspective
    Richard Kones
    The Cardiometabolic Research, Institute, Houston, TX 77054, USA
    Drug Des Devel Ther 4:383-413. 2010
  8. doi Is prevention a fantasy, or the future of medicine? A panoramic view of recent data, status, and direction in cardiovascular prevention
    Richard Kones
    Cardiometabolic Research Institute and Institute for Spirituality and Health at Texas Medical Center, 8181 Fannin Street, U314, Houston, TX 77054, USA
    Ther Adv Cardiovasc Dis 5:61-81. 2011
  9. pmc Recent advances in the management of chronic stable angina I: approach to the patient, diagnosis, pathophysiology, risk stratification, and gender disparities
    Richard Kones
    The Cardiometabolic Research Institute, Houston, Texas 77054, USA
    Vasc Health Risk Manag 6:635-56. 2010
  10. pmc Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes
    Richard Kones
    Cardiometabolic Research Institute, Houston, TX, USA
    Vasc Health Risk Manag 9:617-70. 2013

Detail Information

Publications11

  1. pmc Recent advances in the management of chronic stable angina II. Anti-ischemic therapy, options for refractory angina, risk factor reduction, and revascularization
    Richard Kones
    Cardiometabolic Research Institute, Houston, Texas 77055, USA
    Vasc Health Risk Manag 6:749-74. 2010
    ..Optimal medical therapy, percutaneous coronary intervention, and surgery are not competing therapies, but are complementary and form a continuum, each filling an important evidence-based need in modern comprehensive management...
  2. pmc Mitochondrial therapy for Parkinson's disease: Neuroprotective pharmaconutrition may be disease-modifying
    Richard Kones
    Cardiometabolic Research Institute, Houston, TX, USA
    Clin Pharmacol 2:185-98. 2010
    ..Use of long-chain omega-3 fatty acids and vitamin D in PD are also topics of current interest...
  3. doi Reducing residual risk: modern pharmacochemistry meets old-fashioned lifestyle and adherence improvement
    Richard Kones
    Cardiometabolic Research Institute Inc, 8181 Fannin Street, U314 Houston, TX 77055, USA
    Ther Adv Cardiovasc Dis 7:169-82. 2013
    ....
  4. ncbi The Jupiter study, CRP screening, and aggressive statin therapy-implications for the primary prevention of cardiovascular disease
    Richard Kones
    Cardiometabolic Research Institute, Houston, TX 77054 USA
    Ther Adv Cardiovasc Dis 3:309-15. 2009
    ..Approximately 4.3% of the population satisfies Jupiter inclusion criteria. A review of the assessment of cardiovascular risk is under way at the National Institutes of Health to guide practitioners...
  5. doi Oxygen therapy for acute myocardial infarction-then and now. A century of uncertainty
    Richard Kones
    Cardiometabolic Research Institute, Houston, TX, USA
    Am J Med 124:1000-5. 2011
    ..Clinical guidelines appear to be changing, favoring use of oxygen only in hypoxemic patients, and then cautiously titrating to individual oxygen tensions...
  6. pmc Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey
    Richard Kones
    The Cardiometabolic Research Institute, Houston, TX 77054, USA
    Drug Des Devel Ther 5:325-80. 2011
    ....
  7. pmc Rosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease--a perspective
    Richard Kones
    The Cardiometabolic Research, Institute, Houston, TX 77054, USA
    Drug Des Devel Ther 4:383-413. 2010
    ..Two side effects of interest are myotoxicity and an increase in the incidence of diabetes...
  8. doi Is prevention a fantasy, or the future of medicine? A panoramic view of recent data, status, and direction in cardiovascular prevention
    Richard Kones
    Cardiometabolic Research Institute and Institute for Spirituality and Health at Texas Medical Center, 8181 Fannin Street, U314, Houston, TX 77054, USA
    Ther Adv Cardiovasc Dis 5:61-81. 2011
    ..Environmental and social changes will be necessary, along with major supportive adjustments in the food industry and the assistance of the media. Cooperation is critical to the success of such an initiative...
  9. pmc Recent advances in the management of chronic stable angina I: approach to the patient, diagnosis, pathophysiology, risk stratification, and gender disparities
    Richard Kones
    The Cardiometabolic Research Institute, Houston, Texas 77054, USA
    Vasc Health Risk Manag 6:635-56. 2010
    ..Part II of this two part series will address anti-ischemic therapies, new agents, cardiovascular risk reduction, options to treat refractory angina, and revascularization...
  10. pmc Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes
    Richard Kones
    Cardiometabolic Research Institute, Houston, TX, USA
    Vasc Health Risk Manag 9:617-70. 2013
    ..Comprehensive, intensive, multimechanistic, global, and national programs using primordial, primary, and secondary prevention to lower the total level of cardiovascular risk are necessary. ..
  11. ncbi Prevention of cardiovascular disease: updating the immensity of the challenge and the role of risk factors
    Richard Kones
    The Cardiometabolic Research Institute, Houston, TX
    Hosp Pract (1995) 42:92-100. 2014
    ..For reasons outlined, the solution to this problem is multifaceted and extends well beyond the delivery of medical care into the structure of society and the environment. ..